HER2 Ile655Val and PTEN IVS4 polymorphisms in patients with breast cancer

[1]  I. Dahabreh,et al.  Lack of replication for the association between HER2 I655V polymorphism and breast cancer risk: a systematic review and meta-analysis. , 2011, Cancer Epidemiology.

[2]  M. Yağmurdur,et al.  HER-2/neu gene codon 655 (Ile/Val) polymorphism in breast carcinoma patients. , 2011, Genetic testing and molecular biomarkers.

[3]  H. Bağcı,et al.  P53 codon 72 and HER2 codon 655 polymorphisms in Turkish breast cancer patients. , 2010, DNA and cell biology.

[4]  Zhanwei Wang,et al.  HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case–control studies , 2010, Breast Cancer Research and Treatment.

[5]  Yue Chen,et al.  PTEN mutation spectrum in breast cancers and breast hyperplasia , 2010, Journal of Cancer Research and Clinical Oncology.

[6]  A. Khabir,et al.  HER2 polymorphisms and breast cancer in Tunisian women. , 2010, Genetic testing and molecular biomarkers.

[7]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[8]  M. Rué,et al.  Estimation of age- and stage-specific Catalan breast cancer survival functions using US and Catalan survival data , 2009, BMC Cancer.

[9]  Ruifa Han,et al.  HER2 codon 655 polymorphism and breast cancer risk: a meta-analysis , 2009, Breast Cancer Research and Treatment.

[10]  C. Yip,et al.  Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases. , 2008, Neoplasma.

[11]  I. Helvacı,et al.  The influence of HER2 genotypes as molecular markers on breast cancer outcome. , 2008, DNA and cell biology.

[12]  Nazneen Rahman,et al.  Genetic predisposition to breast cancer: past, present, and future. , 2008, Annual review of genomics and human genetics.

[13]  D. Wen,et al.  PTEN polymorphisms and the risk of esophageal carcinoma and gastric cardiac carcinoma in a high incidence region of China. , 2008, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[14]  M. Hou,et al.  A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan. , 2008, Clinical biochemistry.

[15]  A. Paradiso,et al.  655Val and 1170Pro ERBB2 SNPs in Familial Breast Cancer Risk and BRCA1 Alterations , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[16]  D. Easton,et al.  HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer , 2006, British Journal of Cancer.

[17]  Nazneen Rahman,et al.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles , 2006, Nature Genetics.

[18]  Nazneen Rahman,et al.  ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles , 2006, Nature Genetics.

[19]  S. Bojesen,et al.  Increased risk of breast cancer associated with CHEK2*1100delC. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  David J Hunter,et al.  The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk , 2005, Pharmacogenetics and genomics.

[21]  A. Lambropoulos,et al.  The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. , 2005, Cancer letters.

[22]  H. An,et al.  Her2V655 genotype and breast cancer progression in Korean women , 2005 .

[23]  R. Millikan,et al.  HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case–control analyses , 2005, Breast Cancer Research and Treatment.

[24]  D. Pinto,et al.  HER2 polymorphism and breast cancer risk in Portugal , 2004, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[25]  N. Dalay,et al.  Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. , 2004, Experimental and molecular pathology.

[26]  G. Mills,et al.  The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. , 2001, Seminars in oncology.

[27]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  I. Campbell,et al.  Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. , 2001, Journal of the National Cancer Institute.

[29]  P. Kantoff,et al.  PTEN polymorphism (IVS4) is not associated with risk of prostate cancer. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[30]  R. Parsons,et al.  PTEN: life as a tumor suppressor. , 2001, Experimental cell research.

[31]  X. Shu,et al.  Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. , 2000, Journal of the National Cancer Institute.

[32]  F. Couch,et al.  Polymorphisms in PTEN in breast cancer families , 1999, Journal of medical genetics.

[33]  M. Akashi,et al.  Li-Fraumeni syndrome and the role of the p53 tumor suppressor gene in cancer susceptibility. , 1998, Clinical obstetrics and gynecology.

[34]  M. Nelen,et al.  Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. , 1997, Human molecular genetics.

[35]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[36]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[37]  H. J. Evans,et al.  p53 mutations in breast cancer. , 1992, Cancer research.

[38]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[39]  Yanlei Ma,et al.  Lack of association between HER2 codon 655 polymorphism and breast cancer susceptibility: meta-analysis of 22 studies involving 19,341 subjects , 2010, Breast Cancer Research and Treatment.

[40]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[41]  I. Tentes,et al.  Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer. , 2007, Neoplasma.

[42]  L. Plank,et al.  HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia. , 2006, Neoplasma.

[43]  N. Kim,et al.  Her2 genotype and breast cancer progression in Korean women. , 2005, Pathology international.